While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Experts call for integrated, evidence-based approaches to tackle rising dengue, malaria, and chikungunya burden in Indian cities
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
Dr Shivkumar Kalyanaraman emphasizes need for quality research, partnerships, and measurable outcomes
Experts highlighted that robust pharmacopoeial frameworks are essential for maintaining the quality, safety and efficacy of medicines
The grant backed by Novartis to strengthen academia-industry collaboration across all seven NIPERs
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
At launch of updated pediatric gastroenterology textbook, Union Minister says technology must strengthen not substitute core medical learning
Subscribe To Our Newsletter & Stay Updated
